Biocon Receives U.S. FDA Approval for Yesintek Single-Dose Autoinjector

What Happened ?

Biocon Limited announced on August 18, 2026 that its subsidiary in the United States has received supplemental U.S. FDA approval for Yesintek® 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjectors. 

Yesintek® was originally approved by the U.S. FDA on November 29, 2024. The latest supplemental approval expands the product’s available delivery formats through single-dose prefilled autoinjectors. 

The company stated that the new delivery format provides patients with another treatment option and supports more tailored treatment approaches across different care settings and patient needs.

key details

Yesintek® FDA Approval:

• Product: Yesintek® (ustekinumab-kfce)
• Regulatory Authority: U.S. Food and Drug Administration
• Approval Type: Supplemental approval
• New Format: Single-dose prefilled autoinjector
• Strengths: 45 mg/0.5 ml and 90 mg/ml
• Original FDA Approval: November 29, 2024

Therapeutic Applications:

Yesintek® is indicated for the treatment of:

• Moderate to severe plaque psoriasis in adult and pediatric patients aged 6 years and older.
• Active psoriatic arthritis in adult and pediatric patients aged 6 years and older.
• Moderate to severely active Crohn’s disease in adults.
• Moderate to severely active ulcerative colitis in adults. 

Portfolio Impact:

The supplemental approval expands Biocon’s immunology product portfolio in the United States by adding another delivery format for Yesintek®. The company stated that the approval reinforces its commitment to improving access to affordable medicines.

Note:

• The uploaded disclosure does not provide expected sales, pricing, market-share estimates, launch timelines, licensing economics or incremental earnings contribution from the newly approved autoinjector format.
• No financial impact has therefore been assumed.

Risk Analysis

Summary:

• The FDA approval is a positive regulatory development, but the filing does not quantify its commercial impact. The eventual contribution to Biocon’s U.S. business will depend on adoption of the new delivery format and broader commercial execution.

Key Risks:

• The company has not disclosed expected revenue or earnings contribution from the new format.
• No market-share or sales guidance has been provided in the announcement.
• The disclosure does not specify the commercial launch timeline for the newly approved autoinjectors.
• Commercial uptake of the new delivery format remains unquantified.
• The filing does not provide pricing or reimbursement details.

Worst Case:

• Slower-than-expected adoption of the single-dose prefilled autoinjector could limit its incremental commercial contribution despite the regulatory approval.

Risk Level: Low

Company Commentary

• Biocon stated that its U.S. subsidiary has received supplemental FDA approval for Yesintek® 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjectors. 
• The company said the new delivery format provides patients with another important treatment option. 
• Biocon stated that the autoinjector format supports more tailored treatment approaches across different care settings and patient needs. 
• The company highlighted that the approval enhances its comprehensive immunology portfolio in the United States. 
• Biocon reaffirmed its commitment to improving access to affordable medicines for patients globally.